Aducanumab
AC Immune’s Stock Climbs Following Mixed Phase 2 Trial Results for Alzheimer’s Disease Drug
2021-09-01
Aftermath of Biogen’s Alzheimer’s Drug Approval Continues as Some Hospitals, Insurers Refuse Administration
2021-07-18
Lilly’s Positive Data for Alzheimer’s Drug Bodes Well for Candidates Rooted in Amyloid Hypothesis
2021-03-14
LATEST
BIO 2023 Coming to Boston, with Over 60 Taiwanese Organizations to Share their Achievements
2023-06-02
2023 ASGCT Annual Meeting: Showcase of Exciting New Research, with a Focus on Clinical Applications
2023-06-02
EVENT
2023-06-05
Redefining Early Stage Investments (RESI) 2023 conference series – RESI Boston
Boston, USA